Primaquine
General Information
Antimalarial
Unlicensed Restricted formulary antimicrobial: For details see OUH netFormulary
For all information regarding interactions, contraception, pregnancy and breastfeeding and additional information, see BNF and Summary of Product Characteristics (SPC).
Dosing
|
Indication |
Oral dose |
|
Non-falciparum malaria caused by Plasmodium ovale infection |
15mg od |
|
Non-falciparum malaria caused by Plasmodium vivax infection |
30mg od |
|
Non-falciparum malaria caused by Plasmodium vivax or Plasmodium ovale infection, in patients with mild G6PD deficiency |
45mg once weekly |
|
Treatment of pneumocystis jirovecci pneumonia (PJP) in combination with clindamycin, as a second-line option where allergic/intolerant to co-trimoxazole |
30mg od |
Renal and hepatic impairment
Renal impairment
- No dose adjustment required.
- HD: Not dialysed. Dose as in normal renal function.
- HDF/High Flux/PD: Unknown dialysability. Dose as in normal renal function.
This information is from the Renal Drug Database.
Hepatic impairment
No information available for use in hepatic impairment.
References
- Sanofi-Aventis US. Primaquine phosphate tablets USP [Internet]. Last revision of the text: February 2026. Available from: https://products.sanofi.us/primaquine/primaquine.pdf Accessed 28/4/26
- British National Formulary. Primaquine. BNF online accessed via www.medicinescomplete.com Accessed 28/4/26.
- The Renal Drug Database. Primaquine Phosphate. Last updated 23/9/24 Accessed via https://renaldrugdatabase.com Accessed 28/4/26.
- Sanford guide [online]. Primaquine Phosphate. Last updated 6/4/26. Accessed via https://webedition.sanfordguide.com Accessed 21/4/26